Ultimovacs ASA (OSL:ULTI)
kr 7.45 -0.1 (-1.32%) Market Cap: 256.32 Mil Enterprise Value: 38.98 Mil PE Ratio: 0 PB Ratio: 0.99 GF Score: 30/100

Ultimovacs ASA at ABGSC Investor Days Transcript

Mar 08, 2022 / 12:30PM GMT
Release Date Price: kr69.4 (+4.68%)
Adam Karlsson
ABG Sundal Collier Holding ASA - Analyst

Hi. My name is Adam Karlsson. I'm a healthcare analyst here at ABG, and it's my pleasure to introduce the next company and the next presenter, which is Carlos de Sousa, CEO of Ultimovacs. Carlos, the floor is yours.

Carlos de Sousa
Ultimovacs ASA - CEO

Thank you, Adam, and good afternoon, everybody. I'm the CEO of Ultimovacs, a biotech company located in Oslo. We have 26 employees.

If we can move to the next slide. As we are a publicly listed company, I need to show you this slide, but we can move to the next one. As a company, we operate in the treatment of cancer with what we call next-generation universal cancer vaccine. Our vaccine boosts the anti-tumor response. What does this mean? This means that we help the immune system to identify and kill cancer cells. And we do this by recognizing a special target in the cancer cells called telomerase, and 85% to 90% of cancers in all stages of disease express this telomerase.

And we are a truly off-the-shelf vaccine, ready to be

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot